¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"low malignant potential tumor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
  • miniature endplate potential
    ²¿¸¶Á¾¸»ÆÇÀüÀ§, ¹Ì¼¼Á¾¸»ÆÇÀüÀ§
  • monophasic action potential
    ´Ü»óȰµ¿ÀüÀ§
  • motor evoked potential
    ¿îµ¿À¯¹ßÀüÀ§
  • myotonic potential
    ±Ù(À°)±äÀåÀüÀ§
  • maximal diastolic potential
    ÃÖ´ëÀ̿ϱâÀüÀ§
  • membrane potential
    ¸·ÀüÀ§
  • near field potential
    ±ÙÁ¢ºÎÀ§ÀüÀ§
  • negative potential
    À½ÀüÀ§
  • nerve action potential
    ½Å°æÈ°µ¿ÀüÀ§
  • oscillatory potential
    Áøµ¿¼ÒÆÄÀüÀ§
  • overshooting potential
    Áö³ªÄ¡±âÀüÀ§
  • oxidation-reduction potential
    »êȭȯ¿øÀüÀ§
  • pacemaker potential
    ±æÀâÀÌÀüÀ§, ¹Úµ¿Á¶À²±âÀüÀ§
  • plate potential
    ÆÇÀüÀ§
  • plateau potential
    °í¿øÀüÀ§, Á¤Á¡Áö¼ÓÀüÀ§
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
  • electrotonic potential
    Àü±â±äÀåÀüÀ§
  • end plate potential
    Á¾ÆÇÀüÀ§, Á¾¸»ÆÇÀüÀ§
  • endocochlear potential
    ¿Í¿ì³»ÀüÀ§
  • evoked potential
    À¯¹ßÀüÀ§
  • excitatory junctional potential
    ÈïºÐÁ¢ÇÕºÎÀüÀ§
  • excitatory postsynaptic potential
    ÈïºÐ½Ã³À½ºÈÄÀüÀ§, ÈïºÐ¿¬Á¢ÈÄÀüÀ§
  • potential energy
    À§Ä¡¿¡³ÊÁö, ÀüÀ§¿¡³ÊÁö
  • fibrillation potential
    Àܶ³¸²ÀüÀ§, ¼¼µ¿ÀüÀ§
  • generator potential
    ¹ß»ý±âÀü¾Ð, ±âµ¿ÀüÀ§
  • giant potential
    °Å´ëÀüÀ§
  • potential gradient
    ÀüÀ§±â¿ï±â, ÀüÀ§Â÷
  • inhibitory postsynaptic potential
    ¾ïÁ¦½Ã³ÀÈÄÀüÀ§, ¾ïÁ¦¿¬Á¢ÈÄÀüÀ§
  • junctional potential
    Á¢ÇÕºÎÀüÀ§
  • maximal diastolic potential
    ÃÖ´ëÀ̿ϱâÀüÀ§
  • membrane potential
    ¸·ÀüÀ§
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
  • malignant clear cell hidradenoma
    ¾Ç¼º Åõ¸í¼¼Æ÷ ÇѼ±Á¾
  • malignant degeneration
    ¾Ç¼º º¯¼º
  • malignant degeneration
    ¾Ç¼ºÈ­(¡­ûù)
  • malignant diphtheria
    ¾Ç¼ºµðÇÁÅ׸®¾Æ.
  • malignant diphtheria
    ¾Ç¼ºµðÇÁÅ׸®¾Æ.
  • malignant eccrine poroma
    ¾Ç¼º ¿¡Å©¸° ÇѰøÁ¾
  • malignant eccrine spiradenoma
    ¾Ç¼º ¿¡Å©¸° ³ª¼±Á¾
  • malignant external otitis
    ¾Ç¼º¿ÜÀ̵µ¿°
  • malignant fibrous histiocytoma
    ¾Ç¼º ¼¶À¯¼ºÁ¶Á÷±¸Á¾
  • malignant glaucoma
    ¾Ç¼º³ì³»Àå(¡­ÖàÒ®î¡).
  • malignant goiter
    ¾Ç¼º°©»ó¼±Á¾(¡­Ë£ßÒàÍðþ).
  • malignant goiter
    ¾Ç¼º°©»ó¼±Á¾(¡­°©»ó¼±Á¾).
  • malignant granuloma
    ¾Ç¼ºÀ°¾ÆÁ¾(¡­ë¿ä´ðþ).
  • malignant granuloma
    ¾Ç¼ºÀ°¾ÆÁ¾(¡­ë¿ä´ðþ)
  • malignant granuloma
    ¾Ç¼ºÀ°¾ÆÁ¾
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 10
TSA technical surgical assistance; toluene sulfonic acid; total shoulder arthroplasty; total solute abso...
TSTA toxoplasmin skin test antigen; tumor-specific tissue antigen; tumor-specific transplantation antigen...
131I radioactive Iodine(used in Thyroid uptake, Liver & Kidney Scans & Treatment of malignant & nonmalig...
MFH Malignant Fibrous Histocytoma
MH Malignant Hyperthermia
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 10
BSPM Body surface potential mapping
BAEP Brain stem auditory evoked potential
CAP Child Abuse Potential
CM Cochlear microphonic potential
CAP Compound Action Potential
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • masculinizing tumor
    ³²¼ºÈ­ Á¾¾ç
  • melanotic neuroectodermal tumor
    Èæ»ö¼º ½Å°æ ¿Ü¹è¿± Á¾¾ç
  • mesenchymal odontogenic tumor
    °£¿±¼º Ä¡¼º Á¾¾ç
  • mesenchymal tumor
    Á߹迱¼º Á¾¾ç
  • mesenteric tumor
    Àå°£¸· Á¾¾ç
  • metastatic bone tumor
    ÀüÀ̼º °ñ Á¾¾ç
  • metastatic tumor
    ÀüÀ̼º Á¾¾ç, ÀüÀÌ Á¾¾ç
  • mixed mesodermal tumor
    È¥ÇÕ Á߹迱¼º Á¾¾ç, È¥ÇÕ¼º Á߹迱¼º Á¾¾ç
  • mixed odontogenic tumor
    È¥ÇÕ Ä¡¼º Á¾¾ç
  • mixed tumor
    È¥ÇÕÁ¾, È¥ÇÕ Á¾¾ç
    µ¿ÀǾî=
  • monogerminal mixed tumor
    ´Ü ¹è¿±¼º È¥ÇÕ Á¾¾ç
  • mucoepidermoid tumor
    Á¡¸· À¯Ç¥ÇÇ ¾Ï, Á¡¾× Ç¥ÇǾç Á¾¾ç
  • mucosal-colored tumor
    Á¡¸·»ö Á¾¾ç
  • mucous tumor
    Á¡¾×Á¾
  • multiple vascular tumor
    ´Ù¹ß¼º Ç÷°ü Á¾¾ç
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
malignant melanoma in situ A melanoma limited to the epidermis and composed of nests of atypical melanocytes and scattered single cells extending into the upper epidermis; local excision is curative although the lesion, if untreated, may soon invade the dermis. Malignant lentigo may be considered a slowly progressive type of malignant melanoma in situ.
(05 Mar 2000)
malignant melanoma: staging <radiology> Clark staging: level I: all tumour cells above basement membrane (in situ), level II: tumour extends to papillary dermis, level III: tumour extends to interface between papillary and reticular dermis, level IV: tumour extends between bundles of collagen of reticular dermis, level V: tumour invasion of sucutaneous tissue (87% metastases) Breslow staging: thin: less than 0.75 mm depth of invasion, intermediate: 0.76 - 3.99 mm depth of invasion, thick: greater than 4 mm depth of invasion see: malignant melanoma
(12 Dec 1998)
malignant meningioma <tumour> Meningioma that either invades brain parenchyma or metastasizes.
(05 Mar 2000)
malignant mesothelioma <oncology, tumour> A mesothelioma is a tumour of the lining of the lung and chest cavity, known as the pleura. Benign mesotheliomas do occur but are much more rare than the malignant type. Malignant mesothelioma affects men more commonly and about 80% of cases have a history for prior exposure to asbestos.
Symptoms include chest pain, shortness of breath, cough and weight loss.
(27 Sep 1997)
malignant midline reticulosis An obsolete term for polymorphic reticulosis
(05 Mar 2000)
malignant mixed mullerian tumour A sarcoma of the body of the uterus arising in older women, composed of more than one mesenchymal tissue, especially including striated muscle cells.
Synonym: malignant mixed mullerian tumour.
(05 Mar 2000)
malignant mole syndrome <syndrome> Irregularly shaped, variously coloured, distinctively melanocytic, 5 to 10 mm nevi occurring in large numbers (to over 100) primarily on the trunk and extremities, with a high risk of malignancy reported in several members and three generations of a family.
(05 Mar 2000)
malignant myopia pathologic myopia
malignant nephrosclerosis The renal changes in malignant hypertension; subcapsular petechiae, necrosis in the walls of scattered afferent glomerular arterioles, and red blood cells and casts in the urine, with uraemia as a common termination.
(05 Mar 2000)
malignant oedema An acute toxaemia of cattle, horses, sheep, goats, and pigs caused by the bacterium Clostridium septicum and characterised by edematous swellings around the entry wound, anorexia, high fever, and death.
(05 Mar 2000)
malignant pustule The skin of B. Anthracis infection characteristic lesion that begins as a papule and soon becomes a vesicle and breaks, discharging a bloody serum; the seat of this vesicle, in about 36 hours, becomes a bluish black necrotic mass; constitutional symptoms of septicaemia are severe: high fever, vomiting, profuse sweating, and extreme prostration; the infection is often fatal.
Synonym: malignant pustule.
(05 Mar 2000)
malignant scleritis Progressive inflammation of the anterior sclera and adjacent choroid with associated uveitis.
(05 Mar 2000)
malignant smallpox Malignant smallpox, usually of the haemorrhagic form.
Synonym: malignant smallpox.
Variola miliaris, a form of varioloid in which the eruption consists of miliary vesicles without the formation of pustules.
(05 Mar 2000)
malignant stupor A stuporous condition from which recovery is infrequent, as opposed to benign stupor.
(05 Mar 2000)
malignant synovioma <radiology> Soft-tissue mass, usually about 1 cm from joint, amorphous calcifications (33%), most common at knee, bone erosion (wide zone of transition), juxta-articular osteoporosis Cf: pigmented villonodular synovitis (PVS)
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 10
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 10
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 10
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 10
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 10
ÅëÇÕ°Ë»ö ¿Ï·á